This report provides comprehensive information on the therapeutic development for Brain Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Brain Cancer and special features on late-stage and discontinued projects. http://www.researchmoz.us/brain-cancer-pipeline-review-h1-2015-report.html

1. Brain Cancer - Pipeline Review, H1 2015
Global Markets Directs, Brain Cancer Pipeline Review, H1 2015, provides an overview of the Brain Cancers therapeutic pipeline.
This report provides comprehensive information on the therapeutic development for Brain Cancer, complete with comparative analysis at various stages,
therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured
news and press releases. It also reviews key players involved in the therapeutic development for Brain Cancer and special features on late-stage and discontinued
projects.
Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built
using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and
featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team. Drug
profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the
latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that
the most recent developments are captured on a real time basis.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by
identifying new targets and MOAs to produce first-in-class and best-in-class products.
Scope
The report provides a snapshot of the global therapeutic landscape of Brain Cancer The report reviews key pipeline products under drug profile section which
includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities The report reviews key players involved
in the therapeutics development for Brain Cancer and enlists all their major and minor projects The report summarizes all the dormant and discontinued pipeline
projects A review of the Brain Cancer products under development by companies and universities/research institutes based on information derived from
company and industry-specific sources Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and
undisclosed stages A detailed assessment of monotherapy and combination therapy pipeline projects Coverage of the Brain Cancer pipeline on the basis of target,
MoA, route of administration and molecule type Latest news and deals relating related to pipeline products
Reasons to buy
Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies Identify emerging players
with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage Develop strategic initiatives by understanding the
focus areas of leading companies Identify and understand important and diverse types of therapeutics under development for Brain Cancer Plan mergers and
acquisitions effectively by identifying key players of the most promising pipeline Devise corrective measures for pipeline projects by understanding Brain Cancer
pipeline depth and focus of Indication therapeutics Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most
attractive projects to enhance and expand business potential and scope Modify the therapeutic portfolio by identifying discontinued projects and understanding
the factors that drove them from pipeline
table Of Contents 2
list Of Tables 6
list Of Figures 7
introduction 8
global Markets Direct Report Coverage 8
brain Cancer Overview 9
therapeutics Development 10
pipeline Products For Brain Cancer Overview 10
pipeline Products For Brain Cancer Comparative Analysis 11
brain Cancer Therapeutics Under Development By Companies 12
brain Cancer Therapeutics Under Investigation By Universities/institutes 16
brain Cancer Pipeline Products Glance 17
late Stage Products 17
clinical Stage Products 18
early Stage Products 19
brain Cancer Products Under Development By Companies 20
brain Cancer Products Under Investigation By Universities/institutes 24
brain Cancer Companies Involved In Therapeutics Development 25
abbvie Inc. 25
angiochem Inc. 26
arrien Pharmaceuticals, Llc 27
bbb Therapeutics B.v. 28
bioasis Technologies Inc. 29
bionomics Limited 30
bristol-myers Squibb Company 31
cavion Llc 32
critical Outcome Technologies Inc. 33
curefaktor Pharmaceuticals, Llc 34
diffusion Pharmaceuticals Llc 35
e-therapeutics Plc 36
Brain Cancer - Pipeline Review, H1 2015

2. eisai Co., Ltd. 37
exelixis, Inc. 38
glaxosmithkline Plc 39
hutchison Medipharma Limited 40
merrimack Pharmaceuticals, Inc. 41
nanobiotix 42
nektar Therapeutics 43
nerviano Medical Sciences S.r.l. 44
neuralstem, Inc. 45
novartis Ag 46
oncology Research International Limited 47
pfizer Inc. 48
philogen S.p.a. 49
phosplatin Therapeutics 50
prana Biotechnology Limited 51
puma Biotechnology, Inc. 52
radiorx, Inc. 53
sagetis Biotech, S.l. 54
sanofi 55
spectrum Pharmaceuticals, Inc. 56
stemline Therapeutics, Inc. 57
takeda Pharmaceutical Company Limited 58
thrombogenics Nv 59
tocagen Inc. 60
zymeworks Inc. 61
brain Cancer Therapeutics Assessment 62
assessment By Monotherapy Products 62
assessment By Combination Products 63
assessment By Target 64
assessment By Mechanism Of Action 67
assessment By Route Of Administration 70
assessment By Molecule Type 72
drug Profiles 74
(dabrafenib Mesylate + Trametinib Dimethyl Sulfoxide) - Drug Profile 74
2b3-101 - Drug Profile 76
ang-1005 - Drug Profile 78
ang-4043 - Drug Profile 80
arn-7016 - Drug Profile 81
bnc-105 - Drug Profile 82
bt-2111 - Drug Profile 83
cabazitaxel - Drug Profile 84
cabozantinib S-malate - Drug Profile 86
cfakc-4 - Drug Profile 89
coti-2 - Drug Profile 90
dabrafenib Mesylate - Drug Profile 93
dacomitinib - Drug Profile 96
dexanabinol - Drug Profile 98
drug For Brain Metastasis - Drug Profile 100
erismodegib - Drug Profile 101
etirinotecan Pegol - Drug Profile 104
gene Therapy For Brain Cancer - Drug Profile 107
gene Therapy To Activate P53 For Oncology - Drug Profile 108
hmpl-813 - Drug Profile 109
ipilimumab - Drug Profile 110
irinotecan Sucrosofate Liposomal - Drug Profile 113
kml-001 - Drug Profile 116
lapatinib Ditosylate - Drug Profile 118
leq-506 - Drug Profile 122
lucanthone Hydrochloride - Drug Profile 123
mdna-55 - Drug Profile 125
mibefradil Dihydrochloride - Drug Profile 126
monoclonal Antibody For Brain Cancer And Metastatic Breast Cancer - Drug Profile 128
nbtx-iv - Drug Profile 129
neratinib - Drug Profile 130
nimotuzumab - Drug Profile 134
nmse-973 - Drug Profile 137
nsi-566 - Drug Profile 138
oril-007 - Drug Profile 140
Brain Cancer - Pipeline Review, H1 2015

3. pb-357 - Drug Profile 141
pbt-519 - Drug Profile 142
pritumumab - Drug Profile 143
pt-112 - Drug Profile 145
rad-1901 - Drug Profile 146
radretumab - Drug Profile 148
rrx-001 - Drug Profile 150
sag-002 - Drug Profile 151
sag-003 - Drug Profile 152
siomycin A - Drug Profile 153
sl-301 - Drug Profile 154
sl-302 - Drug Profile 155
small Molecule For Brain Cancer - Drug Profile 156
small Molecule For Brain Cancer And Malignant Glioma - Drug Profile 157
small Molecule For Oncology - Drug Profile 158
small Molecules To Inhibit Hedgehog Signaling For Medulloblastoma - Drug Profile 159
tb-403 - Drug Profile 160
tbx-02 - Drug Profile 162
tpi-287 - Drug Profile 163
transcrocetinate Sodium - Drug Profile 165
ttl-1177 - Drug Profile 166
ubidecarenone - Drug Profile 167
vaccine For Glioblastoma Multiforme - Drug Profile 169
veliparib - Drug Profile 170
vocimagene Amiretrorepvec + Flucytosine Er - Drug Profile 173
brain Cancer Recent Pipeline Updates 175
brain Cancer Dormant Projects 244
brain Cancer Discontinued Products 248
brain Cancer Product Development Milestones 249
featured News & Press Releases 249
appendix 258
methodology 258
coverage 258
secondary Research 258
primary Research 258
expert Panel Validation 258
contact Us 259
disclaimer 259
ResearchMoz(http://www.researchmoz.us/) is the one stop online destination to find and buy market research reports & Industry Analysis. We fulfill all your
research needs spanning across industry verticals with our huge collection of market research reports. We provide our services to all sizes of organizations and
across all industry verticals and markets. Our Research Coordinators have in-depth knowledge of reports as well as publishers and will assist you in making an
informed decision by giving you unbiased and deep insights on which reports will satisfy your needs at the best price.
Contact:
Sales Team,
90 State Street,
Suite 700,
Albany NY - 12207
United States
Tel: +1-518-618-1030
USA - Canada Toll Free 866-997-4948
Email: sales@researchmoz.us
Website: http://www.researchmoz.us/
Brain Cancer - Pipeline Review, H1 2015